Merck & Co. Inc. is shelling out $1.3 billion in cash up front to acquire privately held Eyebiotech Ltd., gaining rights to the latter’s pivotal trial-ready diabetic macular edema drug and a pipeline of earlier-stage candidates targeting vision loss. An additional $1.7 billion could follow in development, regulatory and commercial milestones, raising the deal total to $3 billion. Read More
Interim data from Biohaven Ltd.’s phase I study of BHV-1300, an IgG degrader using an ASGRP-bispecific, produced dose-dependent results in its first four cohorts, though not enough to satisfy investors. Read More
Neuren Pharmaceuticals Ltd.’s NNZ-2591 met the primary endpoints in a phase II trial in children with Pitt Hopkins syndrome, with improvements seen in communication, social interaction, cognition and motor abilities, according to top-line results. Read More
China’s Medilink Therapeutics (Suzhou) Co. Ltd. and Germany’s Biontech SE signed another potential $1 billion-plus deal for novel antibody-drug conjugate (ADC) targets, building off the first ADC-based licensing deal from last year. Read More
Following a significant decline in 2023, private investments in public equity (PIPEs) are rebounding strongly in 2024. Through late May, the collective value of PIPEs has already surpassed the full year 2023 by more than three times, and is also ahead of 2022. Read More
The EU has given the go ahead for a large-scale transnational project that will invest €6.9 billion (US$7.45 billion) to address unmet medical need and fill gaps across the pharmaceutical value chain. Read More
Price is working its way indirectly into licensing agreements for U.S. NIH-funded inventions, be they drugs, biologics, vaccines or medical devices. Read More
New hires and promotions in the biopharma industry, including: Alkeus, Assertio, Compass, Entact, Keros, Kynexis, Montai, Neurocrine, Omega, Tarsier, Vir, Zentalis. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Be, Biogen, Eisai, Genovate, PTC, Sanofi, Sobi, Telix, Vasomune, Vera. Read More
